Subscribe To
HUGE / FSD Pharma incorporates new subsidiary to capitalize on drug development incentives in Australia
Content Topics
Pharma
Incorporates
Subsidiary
Capitalize
Drug
Development
Incentives
Australia
Stock
HUGE
HUGE News
By Accesswire
August 15, 2023
FSD Pharma Selected to Present its Phase 1 Data on Lucid-MS at MSMilan 2023 – 9th Joint ECTRIMS-ACTRIMS Meeting for October 11-13, 2023
Targeting the Approximate $22 Billion Multiple Sclerosis Drug Treatment Market TORONTO, ON / ACCESSWIRE / August 15, 2023 / FSD Pharma Inc. (NASDAQ:HU more_horizontal
By Proactive Investors
January 30, 2023
FSD Pharma says recruiting underway in Phase 2 Trial of FSD201 for treating chronic pain associated with idiopathic MCAS
FSD Pharma Inc (CSE:HUGE, NASDAQ:HUGE) said recruiting is underway for the Phase 2 clinical trial of FSD-PEA (FSD201) for the treatment of chronic p more_horizontal
By Proactive Investors
January 17, 2023
FSD Pharma submits clinical trial application for its multiple sclerosis treatment candidate Lucid-MS
FSD Pharma Inc (CSE:HUGE, NASDAQ:HUGE) announced it has submitted a Clinical Trial Application (CTA) for a planned Phase-1 clinical trial for Lucid-MS more_horizontal
By Proactive Investors
January 13, 2023
FSD Pharma plans buyback of up to 1.9 million shares to utilize cash reserves
FSD Pharma Inc (CSE:HUGE, NASDAQ:HUGE) said its board of directors has approved a share repurchase program that will allow the company to buy back up more_horizontal
By Proactive Investors
January 9, 2023
FSD Pharma incorporates new subsidiary to capitalize on drug development incentives in Australia
FSD Pharma Inc (CSE:HUGE, NASDAQ:HUGE) has announced the incorporation of a new subsidiary to capitalize on drug development incentives in Australia. more_horizontal
By Proactive Investors
November 29, 2022
FSD Pharma announces changes to its board of directors
FSD Pharma Inc (CSE:HUGE, NASDAQ:HUGE) has announced the appointments of Dr Lakshmi P. Kotra and Joseph L. more_horizontal
By Proactive Investors
September 6, 2022
FSD Pharma wins FDA and Health Canada approval for IND for Phase 2 Trial of FSD201 for treating inflammatory disorder
FSD Pharma Inc (CSE:HUGE, NASDAQ:HUGE) revealed that it has received a study may proceed letter for its Investigational New Drug (IND) application fr more_horizontal
By Proactive Investors
May 31, 2022
FSD Pharma submits IND applications to the FDA and Health Canada for Phase 2 clinical trial of FSD-201 to treat an inflammatory disorder
FSD Pharma (CSE:HUGE, NASDAQ:HUGE) Inc has announced that it has submitted Investigation New Drug applications to the US Food and Drug Administration more_horizontal